Global Health

Why is Global Health Ltd falling/rising?

As of 22-Jun, Global Health Ltd's stock price is rising to 1,288.50, with a year-to-date gain of 8.65% and strong long-term performance, including a 99.54% increase over three years. The stock consistently outperforms the Sensex and shows a strong upward trend, supported by high institutional holdings and efficient management.

As of 22-Jun, Global Health Ltd's stock price is rising, currently at 1,288.50, reflecting an increase of 24.2 (1.91%). The stock has shown strong performance over various periods, with a 5.87% increase over the past week and a 4.04% increase over the past month, significantly outperforming the Sensex, which rose only 1.09% and 2.23% respectively during those periods. Year-to-date, the stock has gained 8.65%, while the Sensex has declined by 9.54%. <BR><BR>Additionally, the stock has consistently outperformed the market in the long term, generating a 13.83% return over the last year and an impressive 99.54% over the last three years, compared to the Sensex's declines. Today's performance indicates that Global Health Ltd has outperformed its sector by 1.22% and has experienced consecutive gains over the last five days, accumulating a total return of 5.92% during this period. <BR><BR>The stock also reached an intraday high of Rs 1293, reflecting a 2.27% increase. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Despite a noted decrease in delivery volume, the overall market performance and high management efficiency, evidenced by a return on equity (ROE) of 15.69% and net-debt-free status, contribute positively to investor confidence and the stock's rising price. High institutional holdings at 24.91% further support the stock's stability and growth potential, as these investors typically have better resources to analyze company fundamentals.

Which are the latest news on Global Health?

What does Global Health do?

Global Health Limited provides healthcare services in the hospital industry and is classified as a mid-cap company. As of March 2026, it reported net sales of 1,159 Cr and a net profit of 144 Cr, with a market cap of INR 33,399 Cr.

Overview:<BR>Global Health Limited is engaged in providing healthcare services and operates within the hospital industry, classified as a mid-cap company.<BR><BR>History:<BR>Global Health Limited was incorporated as Global Health Private Limited in 2004. It transitioned to a public limited company on August 11, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 1,159 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 144 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 33,399 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 58.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.04% <BR>Debt-Equity: -0.07 <BR>Return on Equity: 15.83% <BR>Price to Book: 9.01 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Global Health?

As of 10th June, Global Health Ltd has a market capitalization of 33,399.00 Cr, with recent Net Sales of 4,410.20 Cr and a Net Profit of 556.46 Cr.

As of 10th June, Global Health Ltd has a market capitalization of 33,399.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Global Health reported Net Sales of 4,410.20 Cr and a Net Profit of 556.46 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 3,386.41 Cr and Total Assets of 4,733.21 Cr.

Who are in the management team of Global Health?

The management team of Global Health includes Naresh Kumar Trehan (Chairman & Managing Director), Pankaj Prakash Sahni (Group CEO), and several independent and non-executive directors, ensuring a blend of executive leadership and oversight.

The management team of Global Health includes the following key individuals:<BR><BR>1. **Naresh Kumar Trehan** - Chairman & Managing Director<BR>2. **Pankaj Prakash Sahni** - Group CEO & Whole Time Director<BR>3. **Hari S Bhartia** - Independent Non-Executive Director<BR>4. **Praveen Mahajan** - Independent Non-Executive Director<BR>5. **Rajan Bharti Mittal** - Independent Non-Executive Director<BR>6. **Ravi Gupta** - Independent Non-Executive Director<BR>7. **Ravi Kant Jaipuria** - Non-Executive Director (Nominated)<BR>8. **Sunil Sachdeva** - Non-Executive Director<BR>9. **Venkatesh Ratnasami** - Non-Executive Director (Nominated)<BR>10. **Vikram Singh Mehta** - Independent Non-Executive Director<BR><BR>This team brings a mix of executive leadership and independent oversight to the company.

Who are the peers of the Global Health?

Global Health's peers include Apollo Hospitals, Max Healthcare, Fortis Health, Aster DM Health, Narayana Hrudaya, Krishna Institute, Dr Agarwal's Health, Rainbow Child, and Health.Global. In terms of performance, Fortis Health leads with a 1-year return of 27.83%, while Global Health's return is 2.72%.

Peers: The peers of Global Health are Apollo Hospitals, Max Healthcare, Fortis Health, Aster DM Health, Narayana Hrudaya, Krishna Institute, Dr Agarwal's Health, Rainbow Child, and Health.Global.<BR><BR>Quality Snapshot: Excellent management risk is observed at Apollo Hospitals, Narayana Hrudaya, and Rainbow Child, while Average management risk is found at Max Healthcare, Fortis Health, Dr Agarwal's Health, and Health.Global. Good management risk is noted at Aster DM Health, Krishna Institute, and Global Health. For growth, Excellent growth is seen at Apollo Hospitals, Max Healthcare, Fortis Health, and Narayana Hrudaya, while Below Average growth is present at Aster DM Health, Global Health, Krishna Institute, and Rainbow Child. In terms of Capital Structure, Excellent capital structure is noted at Global Health, while Average capital structure is found at Aster DM Health and the rest, and Good capital structure is observed at Fortis Health, Narayana Hrudaya, Krishna Institute, Dr Agarwal's Health, and Rainbow Child.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health at 27.83%, while Max Healthcare has the lowest at -14.68%. Global Health's 1-year return is 2.72%, which is higher than Max Healthcare's but lower than Fortis Health's. Additionally, the peers with negative six-month returns include Max Healthcare, Dr Agarwal's Health, and Health.Global.

Should I buy, sell or hold Global Health Ltd?

Are Global Health Ltd latest results good or bad?

Global Health Ltd's latest results show strong revenue growth of 24.46% and a 42% increase in net profit, but profitability concerns arise from a declining operating margin and rising costs, indicating a cautious outlook for investors.

Global Health Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year net profit increase of 42% to ₹143.99 crores and a robust revenue growth of 24.46%, reaching ₹1,159.05 crores. This revenue figure marks the highest quarterly sales in the company's history, indicating strong demand and operational capacity expansion.<BR><BR>However, there are notable concerns regarding profitability. The operating margin, excluding other income, contracted to 21.03%, down from 24.13% a year ago, reflecting a 310 basis point decline. This margin compression is largely attributed to rising employee costs and increased interest expenses, which surged by 77.77% year-on-year to ₹26.71 crores, marking the highest quarterly interest burden in recent history.<BR><BR>While the company has shown impressive revenue growth, the sustainability of its profit margins is in question due to these rising costs. The interest coverage ratio has also deteriorated, indicating potential financial stress. Overall, while the headline numbers may seem positive, the underlying challenges related to margins and costs suggest a cautious outlook for investors.

When is the next results date for Global Health Ltd?

The next results date for Global Health Ltd is 14 May 2026.

The next results date for Global Health Ltd is scheduled for 14 May 2026.

Is Global Health technically bullish or bearish?

As of December 4, 2025, the market trend is mildly bearish, with bearish signals from the weekly MACD and Bollinger Bands, despite some mixed bullish indicators, suggesting caution in the current environment.

As of 4 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish conditions. The monthly MACD is also mildly bearish, while the daily moving averages show a mildly bullish signal, creating a mixed picture. The KST is bullish on a weekly basis, but the overall trend is influenced by the mildly bearish OBV readings. The Dow Theory reflects a mildly bullish stance on the weekly chart, but with no trend on the monthly. Overall, the bearish indicators outweigh the bullish signals, suggesting caution in the current market environment.

How has been the historical performance of Global Health?

Global Health has shown strong financial growth over the past five years, with net sales increasing from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, alongside significant rises in operating profit and profits before and after tax. Despite challenges in cash flow management, the company has expanded its asset base significantly during this period.

Answer:<BR>The historical performance of Global Health shows a consistent upward trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Global Health's net sales have increased significantly from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025, reflecting a strong growth trajectory. Total operating income followed a similar pattern, rising from INR 1,446.74 crore in March 2021 to INR 3,692.32 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 222.85 crore in March 2021 to INR 956.17 crore in March 2025. Profit before tax increased from INR 32.46 crore in March 2021 to INR 647.26 crore in March 2025, while profit after tax rose from INR 28.81 crore to INR 481.32 crore during the same period. The earnings per share (EPS) showed fluctuations, peaking at INR 60.79 in March 2023 before settling at INR 17.92 in March 2025. On the balance sheet, total assets grew from INR 2,666.29 crore in March 2021 to INR 4,733.21 crore in March 2025, while total liabilities increased from INR 2,668.36 crore to INR 4,733.21 crore. The cash flow from operating activities improved from INR 241 crore in March 2021 to INR 623 crore in March 2025, although the net cash flow showed a decline, ending at INR -194 crore in March 2025 compared to INR -78 crore in March 2021. Overall, Global Health has demonstrated robust growth in revenue and profitability, alongside an expanding asset base, despite some challenges in cash flow management.

Is Global Health overvalued or undervalued?

As of November 19, 2025, Global Health is considered very expensive with a PE ratio of 53.76 and high valuation ratios compared to peers, despite a strong three-year return of 189.89%, indicating it is overvalued in the current market.

As of 19 November 2025, the valuation grade for Global Health has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently deemed overvalued. Key ratios highlight this assessment, with a PE ratio of 53.76, a Price to Book Value of 8.70, and an EV to EBITDA of 33.44, all of which are considerably high compared to industry norms.<BR><BR>In comparison to its peers, Global Health's valuation stands out, particularly when looking at Max Healthcare with a PE of 80.06 and Apollo Hospitals at 64.09. This suggests that while Global Health is indeed very expensive, it is relatively more attractive than some of its peers. Notably, the company has shown a strong return of 189.89% over the past three years, outperforming the Sensex's 38.15% return during the same period, which may contribute to its elevated valuation despite the current market conditions.

Who are the top shareholders of the Global Health?

The top shareholders of Global Health include Naresh Trehan with 33.03%, Dunearn Investments (Mauritius) Pte Ltd at 14.86%, 25 mutual fund schemes holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined 11.76%. Individual investors account for 6.53% of the shareholding.

The top shareholders of Global Health include Naresh Trehan, who is the promoter with the highest holding at 33.03%. The highest public shareholder is Dunearn Investments (Mauritius) Pte Ltd, holding 14.86%. Additionally, the company has 25 mutual fund schemes collectively holding 10.36%, and 158 Foreign Institutional Investors (FIIs) with a combined holding of 11.76%. Individual investors account for 6.53% of the shareholding.

Has Global Health declared dividend?

No Dividend History Available